301 related articles for article (PubMed ID: 33435908)
1. Sub-optimal gain in vision in retinal vein occlusion due to under-treatment in the real world: results from an open-label prospective study of Intravitreal Ranibizumab.
Narayanan R; Kelkar A; Abbas Z; Goel N; Soman M; Naik N; Sudhalkar A; Walinjkar J; Shah U; Maksane N
BMC Ophthalmol; 2021 Jan; 21(1):33. PubMed ID: 33435908
[TBL] [Abstract][Full Text] [Related]
2. Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study.
Glacet-Bernard A; Girmens JF; Kodjikian L; Delcourt C; Fajnkuchen F; Creuzot-Garcher C; San Nicolas N; Massin P
Ophthalmic Res; 2023; 66(1):824-834. PubMed ID: 36972579
[TBL] [Abstract][Full Text] [Related]
3. Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Mitry D; Bunce C; Charteris D
Cochrane Database Syst Rev; 2013 Jan; (1):CD009510. PubMed ID: 23440840
[TBL] [Abstract][Full Text] [Related]
4. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of intravitreal ranibizumab versus standard grid laser for macular edema following branch retinal vein occlusion.
Tan MH; McAllister IL; Gillies ME; Verma N; Banerjee G; Smithies LA; Wong WL; Wong TY
Am J Ophthalmol; 2014 Jan; 157(1):237-247.e1. PubMed ID: 24112635
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
7. Combination of Ranibizumab with macular laser for macular edema secondary to branch retinal vein occlusion: one-year results from a randomized controlled double-blind trial.
Song S; Yu X; Zhang P; Gu X; Dai H
BMC Ophthalmol; 2020 Jun; 20(1):241. PubMed ID: 32560639
[TBL] [Abstract][Full Text] [Related]
8. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
10. Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study.
Wroblewski JJ; Hu AY
Ophthalmic Surg Lasers Imaging Retina; 2016 Oct; 47(10):914-923. PubMed ID: 27759857
[TBL] [Abstract][Full Text] [Related]
11. Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion.
Lloyd Clark W; Liu M; Kitchens J; Wang PW; Haskova Z
BMC Ophthalmol; 2019 Jan; 19(1):11. PubMed ID: 30621653
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial.
Eter N; Mohr A; Wachtlin J; Feltgen N; Shirlaw A; Leaback R;
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):77-87. PubMed ID: 27460280
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
14. Retinal oximetry during treatment of retinal vein occlusion by ranibizumab in patients with high blood pressure and dyslipidemia.
Keilani C; Halalchi A; Wakpi Djeugue D; Regis A; Abada S
J Fr Ophtalmol; 2016 Dec; 39(10):816-821. PubMed ID: 27865689
[TBL] [Abstract][Full Text] [Related]
15. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
16. Results of the first 12 months treatment of macular edema complicating BRVO in patients treated with ranibizumab.
Lalinská L; Krásný J; Studený P; Veith M
Cesk Slov Oftalmol; 2018; 74(2):62-67. PubMed ID: 30441951
[TBL] [Abstract][Full Text] [Related]
17. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
[TBL] [Abstract][Full Text] [Related]
18. Twenty-Four Month Results of Intravitreal Ranibizumab for Macular Edema after Branch Retinal Vein Occlusion: Visual Outcomes and Resolution of Macular Edema.
Inagaki M; Hirano Y; Yasuda Y; Kawamura M; Suzuki N; Yasukawa T; Yoshida M; Ogura Y
Semin Ophthalmol; 2021 Oct; 36(7):482-489. PubMed ID: 33617388
[No Abstract] [Full Text] [Related]
19. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1.
Narayanan R; Panchal B; Das T; Chhablani J; Jalali S; Ali MH;
Br J Ophthalmol; 2015 Jul; 99(7):954-9. PubMed ID: 25631483
[TBL] [Abstract][Full Text] [Related]
20. Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France.
Korobelnik JF; Kodjikian L; Delcourt C; Gualino V; Leaback R; Pinchinat S; Velard ME
Graefes Arch Clin Exp Ophthalmol; 2016 Dec; 254(12):2307-2318. PubMed ID: 27286894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
